Molvarec A, Prohászka Z, Nagy B, Szalay J, Füst G, Karádi I, Rigó J
Department of Obstetrics and Gynecology, Kútvölgyi Clinical Center, Semmelweis University, Budapest, Hungary.
J Hum Hypertens. 2006 Oct;20(10):780-6. doi: 10.1038/sj.jhh.1002060. Epub 2006 Jun 8.
Our aim was to investigate the association between serum heat-shock protein (Hsp) 70 concentration and hypertensive disorders of pregnancy. One hundred and forty-two pregnant women with hypertensive disorders (93 with preeclampsia, 29 with transient hypertension of pregnancy and 20 with superimposed preeclampsia) and 127 normotensive, healthy pregnant women were included in the study. Serum Hsp70 concentration was measured using enzyme-linked immunosorbent assay. The serum Hsp70 concentration was significantly higher in patients with transient hypertension of pregnancy, in preeclamptic patients and in patients with superimposed preeclampsia than in the control group (median (25-75 percentile): 0.66 (0.52-0.84), 0.55 (0.42-0.80), 0.61 (0.42-0.91) ng/ml vs 0.31 (0.27-0.39) ng/ml, respectively; P<0.001). Multivariate logistic regression analysis showed independent association of elevated serum Hsp70 level with transient hypertension of pregnancy, preeclampsia and superimposed preeclampsia. The difference in serum Hsp70 concentration between preeclamptic patients and the control group was statistically significant in each gestational age category. In the groups of preeclamptic and superimposed preeclamptic patients, there was no significant difference in serum Hsp70 concentration between mild and severe preeclamptic patients, between patients with late and early onset of the disease, as well as between preeclamptic patients without and with foetal growth restriction. In conclusion, serum Hsp70 concentration is elevated in transient hypertension of pregnancy, in preeclampsia and in superimposed preeclampsia. Circulating Hsp70 may not only be a marker for these conditions, but might also play a role in their pathogenesis. However, further studies are needed to explore its role in the pathogenesis of hypertensive disorders of pregnancy.
我们的目的是研究血清热休克蛋白（Hsp）70浓度与妊娠期高血压疾病之间的关联。本研究纳入了142例患有高血压疾病的孕妇（93例先兆子痫、29例妊娠期短暂性高血压和20例妊娠合并先兆子痫）以及127例血压正常的健康孕妇。采用酶联免疫吸附测定法检测血清Hsp70浓度。妊娠期短暂性高血压患者、先兆子痫患者和妊娠合并先兆子痫患者的血清Hsp70浓度显著高于对照组（中位数（第25 - 75百分位数）：分别为0.66（0.52 - 0.84）、0.55（0.42 - 0.80）、0.61（0.42 - 0.91）ng/ml，而对照组为0.31（0.27 - 0.39）ng/ml；P<0.001）。多因素逻辑回归分析显示，血清Hsp70水平升高与妊娠期短暂性高血压、先兆子痫和妊娠合并先兆子痫独立相关。在每个孕周类别中，先兆子痫患者与对照组之间血清Hsp70浓度的差异均具有统计学意义。在先兆子痫组和妊娠合并先兆子痫组中，轻度和重度先兆子痫患者之间、疾病早发和晚发患者之间以及有无胎儿生长受限的先兆子痫患者之间，血清Hsp70浓度均无显著差异。总之，妊娠期短暂性高血压、先兆子痫和妊娠合并先兆子痫患者的血清Hsp70浓度升高。循环中的Hsp70不仅可能是这些疾病的一个标志物，还可能在其发病机制中起作用。然而，需要进一步研究以探讨其在妊娠期高血压疾病发病机制中的作用。
